B-containing nanomaterial synthesis when a combustion wave moves within a packed bed of solid particles

Nersisyan, H.,Lee, T.H.,Yoo, B.U.,Kwon, S.C.,Suh, H.,Kim, J.G.,Lee, J.H. Elsevier [etc.] 2016 Combustion and Flame Vol.172 No.-

This study deals with combustion behavior of B<SUB>2</SUB>O<SUB>3</SUB>/Mg/NH<SUB>4</SUB>Cl/C complex systems for the synthesis of amorphous boron (B), boron carbide (B<SUB>4</SUB>C), and boron nitride (BN) nanostructures. The raw mixtures used in the experiments were prepared on the base of a B<SUB>2</SUB>O<SUB>3</SUB>-Mg precursor mixture, which is sufficiently exothermic to maintain a self-propagating regime of the combustion reaction. Thermodynamic analysis of the combustion temperatures and experimental validation indicate that the 1000-1500<SUP>o</SUP>C temperature range is very effective for synthesizing the nanostructures of B, B<SUB>4</SUB>C, and BN. It was found that B-containing functional nanostructures are mainly spherical nanoparticles (B) or nanosheets (B<SUB>4</SUB>C, BN). The phase composition and microstructural characteristics of the final products were evaluated based on the combustion temperature and solid/liquid phase changes.

腫瘍免疫療法 : 特히 胃癌을 中心으로

許景渤,金益洙,兪熙,閔珖植 順天鄕病院 1977 順天鄕醫報 Vol.2 No.1

Carcinoma is one of the most frequently observed malignant tumor in Korean patients. Result of surgery, for instance, in early stomach carcinomais encouraging and it is reported to be about 45% of five year survival rate but cases are few and rare. The majority of cases are that of either unresectable or metastatic regional lymphnode involvement of carcinoma. Their prognosis is poor. In those who had regional lymph node metastasis two year and three year survival rates are reported tobe each 37.1% and 17.9% respectively. Development of tumor immunology of the malignant disease made us greatly interested on the immunotheraly on the post resection stomach carcinoma. Studies on immunological competency by way of D.N.C.B. skin test started from 1971 and few cases those who may understand the new development of additional immuno therapy were selecter for B.C.G. innoculation after the subtotal gastrectomy. Recently monitering of peripheral thymus depentent lymphocytes (T-cell) count were undertaken to correlate the clinical course of the patients with the immunotherapy. In order to evaluate the immunological competency of healthy and all kind of malignant deseases of different stages, study with D.N.C.B. sensitization was undertaken in 264 cases. In healthy men of 53, only one man showed anergy, this anergic man is still healthy after three year observation. Table 1 further demonstrate the incedence of D.N.C.B. anergy in each group of patients, it notes that the unresectable malignant patients showed anergy 77 out of 105 cases(73.3%). From the D.N.C.B. sensirtization studies it may be clear to state that patient's immunological competency inthe malignant disease is severly deteriorated in the advanced tumo patients. The peripheral T-cell count also showed that the advanced malignant patients had lower T-cell count and it is progressively decreasing at the terminal stage(Table 2). In few cases who has B.C.G. after the subtotal gastrectomy the T-cell count are increasing after the treatment(Table 4). In 1971 five partients received B.C.G. therapy after the subtotal gastrectomy and three patients are sill living well. These 5 had all regional lymph node metastasis. The usual three year survival ratein similar patients is about 17 to 20%. Number of B.C.G. cases are not sufficient to a statistical significance but it may suggest a good deal of implication. Chance of two year survival after the B.C.G. therapy may be also far better than non-B.C.G.group(Table 5). The immunotherapy on malignant patients may be controversial, and yet we understand that the malignant tumor patients had impared immunity or immnological ability and that B.C.G. or immunotherapy may be effective on microscopic malignant lesion. In a selected case an immunotherapy after subtotal gastrectomy for gastric carcinoma may offer a beneficial effects on clinical course of the disease.

혈액검체로부터 분리된 황색포도구균의 독소유전자형 및 PFGE 분석

이영선,차정옥,정영희,최연화,양숙자,김홍빈,유재일,김봉수 국립보건연구원 2000 국립보건원보 Vol.37 No.-

DMNQ S-64 Induces Apoptosis via Caspase Activation and Cyclooxygenase-2 Inhibition in Human Nonsmall Lung Cancer Cells

LIM, E.-S.,RHEE, Y.-H.,PARK, M.-K.,SHIM, B.-S.,AHN, K.-S.,KANG, H.,YOO, H.-S.,KIM, S.-H. Wiley (Blackwell Publishing) 2007 Annals of the New York Academy of Sciences Vol.1095 No.1

<P>Shikonin has been reported to induce apoptosis and inhibit angiogenesis in vivo and in vitro. 6-(1-propoxyiminoalkyl)-5,8-dimethoxyoxy 1,4-naphtoquinone S-64 (DMNQ S-64) was synthesized as a shikonin derivative. In this article, the underlying apoptotic mechanism of DMNQ S-64 was examined. DMNQ S-64 exerted cytotoxicity against A549 lung carcinoma cells with IC(50) of 27.3 microM. Apoptotic bodies were observed in DMNQ S-64-treated A549 cells by 4'-6-diamidino-2-phenylindole (DAPI) staining assay. DMNQ S-64 also increased sub-G1 DNA portion in a concentration-dependent manner by flow cytometric analysis. Western blotting has revealed that DMNQ S-64 effectively activates the expression of caspase 8, 9, and 3, cleaves poly (ADP-ribose) polymerase, and increases the ratio of Bax/Bcl-2. Furthermore, cytochrome c was released in a concentration-dependent manner by DMNQ S-64. Similarly, DMNQ S-64 significantly increased caspase 3 activity by enzyme-linked immunosorbent assay (ELISA). It also significantly inhibited the level of prostaglandin E2 (PGE(2)) by ELISA and downregulated the expression of cyclooxygenase-2 (COX-2) in a concentration-dependent manner. Taken together, DMNQ S-64 may exhibit cytotoxicity against A549 cells via caspase activation and COX-2 inhibition.</P>

혈청 HBV bDNA 음성이나 간기능검사 이상을 보인 만성 B형 간염 환자들의 임상상

김상진 ( S. J. Kim ),박중원 ( J. Park ),김진희 ( J. H. Kim ),홍요한 ( Y. H. Hong ),정혜령 ( H. R. Jung ),김형준 ( H. J. Kim ),도재혁 ( J. H. Do ),유병철 ( B. C. Yoo ),박실무 ( S. M. Park ) 대한소화기학회 2002 대한소화기학회 춘계학술대회 Vol.2002 No.-

<목적> B형 간염바이러스(HBV)의 증식이 억제되면 만성 B형 간염의 활동성은 감소되며 이러한 이유에서 라미뷰딘과 같은 항바이러스제들을 치료제로 사용하고 있다. 그러나 HBV의 혈중 농도는 낮으나 간기능검사 이상을 보이는 만성 B형 간염 환자들이 상당수 있어 그 원인 규명이 필요한 실정이다. 이에 연구자들은 혈청 HBV branched DNA(bDNA) 음성인 만성 B형 간염 환자들을 대상으로 간 기능검사 이상과 관련될 수 있는 임상적 원인들을 조사하

刊內膽石症의 分類 및 手術法

許景渤,兪熙,金益洙,閔珖植 順天鄕病院 1976 順天鄕醫報 Vol.1 No.1

Intera-hepatic calculi, whech is a kind of gall stones found in the liver ducts, are frequently encountered during a surgical intervention of cholelithiasis at Korea. It has also been frequently observed in the South-Eastern area of Asia against its rarity in the States. Arather high incidence, perplexing clinical manifestations, controversial surgical treatment and a high reccurrence after an operative treatment are the common features. Dye-dilution operative cholangiogram may help to demonstrate a good delineation of the intra-hepatic calculi due to a sufficient amount of diluted dye (Hypaque) injection. Through this technic it is learned that the intra-hepatic calculi are frequently associated with ductal stenosis and the calculi are often retained in the intra-hepatic ducts proximal to the stenosis. Intrahepatic calculi are classified into 6 different types. As shown in the table, simple intrahepatic calculi are not associated with stenosis. Compound intrahepatic calculi are those that associated with stenosis of duct in some part of the liver, and according to the location of the stenosis drainage function of the corresponding liver segment may be disturbed and they are further subdivided. Type B-1. has stenosis in hepatic hilum. Type B-2. has stenonsis in left lobe of liver. Type B-3. has stenosis in right lobe of liver. difference between posterior and anterior segment of right lobe is clear and it is again divided into type. B-3-A and type B-3-P. Type B-4. has stenosis in both lobes of liver. According to the classified type of intrahepatic calculi surgical treatment may be individualized. Simple intrahepatic calculi are well treated by the conventional By-pass operation. But compound intrahepatec calculi are not responding well to the ordinary By-pass operation. In the compound intrahepatic calculi, drainage operation must be done at a point proximal to the stenosis. In the type B-1. hepatic hilum had to be exposed and Roux-en-Y hepatico-jejunost-omy was done. This 21-years-old man is doing well for over 8 years. In the type B-2. initial operation was Roux-en-Y choledocho-jejunostomy for multiple bilobar intrahepatic calculi, at the time of first operation. It was not aware of the presence of the left hepatic stenosis. 3 months later patient had recurrent pain and fell into a shock. Finally patient underwent partial left hepatec lobectomy and Roux-en-Y hepatico-jejunostomy. In the type B-3. Operative cholangiogram shows marked stenosis of right intrahepatic duct with stones. Cholecystectomy was done and Roux-en-Y type anastomosis between jejunum and side of common bile duct was done first. Dilated right intrahepatic duct was exposed and side to side hepatico-jejunostomy was added. Compound intrahepatic calculi of type B-3-p, where there would be no reasonal drainage operation, hepatec lobectomy may be indicated. Compound intrahepatic calculi of type B-4, are not primarily surgical subjicts but depedend on size of the calculi and patency of the stenosis, some small calculi may be expected to be drained into intestinal lumen and few patients were thus managed. In view of our clinical experiences, convevtional by-pass operation is worth only in the simple type of intrahepatic calculi, and in the compound intrahepatic calculi, operation must be all individualized. Compound type of B-3-P and B-4, however, are not entirely surgical problens.Rescent knowledge of cholesterol gall stone formation and possibility to dissolve it may potentiate management of residual calculi in near furture. Intrahepatec calculi are uaually pigmented stone and pathogenesis must be further investigated.

Salmonella Typhi, Salmonella Enteritidis 및 Salmonella Typhimurium균에 대한 Phage typing 및 antibiogram 분석

신영학,유정식,오경수,이점규,이상원,고운영,양병국 국립보건연구원 2000 국립보건원보 Vol.37 No.-

Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma

Yoon, W.,Park, Y.C.,Kim, J.,Chae, Y.S.,Byeon, J.H.,Min, S.H.,Park, S.,Yoo, Y.,Park, Y.K.,Kim, B.M. Pergamon Press 2017 European journal of cancer Vol.70 No.-

Salmonella have been experimentally used as anti-cancer agents, because they show selective growth in tumours. In this study, we genetically modified attenuated Salmonella typhimurium to express and secrete interferon-gamma (IFN-γ) as a tumouricidal agent to enhance the therapeutic efficacy of Salmonella. IFN-γ was fused to the N-terminal region (residues 1-160) of SipB (SipB160) for secretion from bacterial cells. Attenuated S. typhimurium expressing recombinant IFN-γ (S. typhimurium (IFN-γ)) invaded the melanoma cells and induced cytotoxicity. Subcutaneous administration of S. typhimurium (IFN-γ) also efficiently inhibited tumour growth and prolonged the survival of C57BL/6 mice bearing B16F10 melanoma compared with administration of phosphate-buffered saline (PBS), unmodified S. typhimurium or S. typhimurium expressing empty vector (S. typhimurium [Vec]) in a natural killer (NK) cell-dependent manner. Moreover, genetically modified Salmonella, including S. typhimurium (IFN-γ), showed little toxicity to normal tissues with no observable adverse effects. However, S. typhimurium (IFN-γ)-mediated tumour suppression was attributed to direct killing of tumour cells rather than to stable anti-tumour immunity. Collectively, these results suggest that tumour-targeted therapy using S. typhimurium (IFN-γ) has potential for melanoma treatment.

비육돈에 미생물제제 급여시 분뇨 특성에 미치는 효과

곽정훈,최동윤,박치호,김재환,정광화,양창범,유용희,천현식,라창식,Kwag, J.H.,Choi, D.Y.,Park, Ch.H.,Kim, J.H.,Jeong, K.H.,Yang, Ch.B.,Yoo, Y.H.,Chen, H.S.,La, C.S. 한국축산환경학회 2007 축산시설환경학회지 Vol.13 No.3

본시험은 비육돈사료에 미생물제제를 사료에 미생물제제 A 및 B 0.1 미생물제제 C를 0.2% 혼합 급여할 경우 사료섭취량 및 돈분의 오염물질 배설농도에 미치는 영향을 분석하기 위하여 4처리$\times$반복당 5두로서 총 20두를 공시하여 실시하였는데 그 결과를 요약하면 다음과 같다. 1. 비육돈의 일일 평균사료섭취량은 대조구 3.15 kg/일.두였고 미생물A, B, C구는 각각 3.14kg/일/두, 3.31, 3.42로 미생물제제 C구에서 일일 사료섭취량이 가장 높게 조사되었으며(p<0.05), 2. 일일평균 음수량은 사료섭취량이 높았던 미생물 C구에서 3.95kg/일/두로 가장 높게 조사되었다(p<0.05). 3. 미생물제제 처리구별로 분뇨배설량은 사료섭취량이 높았던 미생물제제 C구에서 가장 많이 배설되는 것으로 조사되었으며(p<0.05), 돈뇨의 배설량도 미생물제제 C구에서 2.23kg/일/두에서 높았다(p<0.05). 4. 돈분뇨의 수분 함량은 및 비료성분인 T-N, $P_{2}O_{5}$, $K_{2}O$ 성분도 처리 간에 큰 차이를 보이지 않았다(p<0.05). 5. 돈분뇨의 평균 BOD 농도는 돈분의 경우 미생물제제 B, C제제 급여구가 유의적으로 높게 조사되었다(p<0.05). 그리고 돈뇨의 BOD의 경우에는 대조구에서 $8,657.5mg/{\ell}$로 가장 높은 것으로 조사되었다(p<0.05). 6. COD 농도는 대조구에서 가장 높게 조사되었으며(p<0.05). 돈뇨의 경우에는 미생물제제 A급여구에서 평균 $9,545mg/{\ell}$로 가장 높았다(p<0.05). 7. SS 농도는 미생물제제 B급여구에서 가장 높게 조사되었으며(p<0.05), 돈분뇨중의 T-N 농도는 처리구간에 유의적인 차이가 나타나지 않았다(p<0.05). 그리고 T-P 농도의 경우에는 미생물제제 C급여구에서 유의적인 차이가 나는 것으로 조사되었다(p<0.05). 이상의 결과를 요약해보면 비육돈에 미생물제제 혼합급여시 사료섭취량과 음수량을 증가시키는데 효과가 있는 것으로 조사되었으나, 비료성분 배설량에는 큰 차이를 보이지 않는 것으로 조사되었으나, BOD 등 오염물질농도의 경우에는 미생물제제 A급여구에서 가장 낮게 조사되어 비육돈사료에 미생물제제 급여시 오염물질 저감효과가 있는 것으로 조사되었다. Study for the effect of three different microbial feed additives(henceforth MA-A, MA-B, and MA-C) on feed coversion rate, and physical and chemical characteristics of swine finisher was conducted. MA-B had higher number of Lactobacillus spp. and yeast, compared to any other. The amylase activity of MA-B was also higher than any other. The daily feed intake rates of pigs fed control, MA-A, MA-B and MA-C were 3.15, 3.14, 3.31 and 3.42 kg, respectively. MA-C had the highest weight gain. However, there was no significant difference between treatments. The weights of feces daily excreted by pigs fed control, MA-A, MA-B, and MA-C were 2.14, 2.02, 2.18, and 2.23 kg/day, respectively. The volume of urine daily excreted by pigs fed control, MA-A, MA-B, and MA-C were 3.14, 3.26, 3.27, and $3.41\;{\ell}/day$, respectively. Water content, T-N, $P_{2}O_{5}$, and $K_{2}O$ in swine manure were not significantly different between treatments. The BOD were between 42,576 and $67,450\;mg/{\ell}$ for feces and were between 5,882.5 and $8,657.5\;mg/{\ell}$ for urine, respectively. The SS were between 138,000 and $180,000\;mg/{\ell}$ for feces and were between 875.0 and $1450.0mg/{\ell}$ for urine, respectively.

Progress in the development of heating systems towards long pulse operation for KSTAR

Kwak, J.G.,Bae, Y.D.,Chang, D.H.,Chang, D.S.,Hong, B.G.,Hwang, C.K.,In, S.R.,Jeong, S.H.,Jin, J.T.,Jung, K.S.,Kim, B.R.,Kim, J.,Kim, S.K.,Kim, T.S.,Lee, D.W.,Lee, K.W.,Oh, B.H.,Seo, C.S.,Seo, M.S.,Yoo International Atomic Energy Agency 2007 Nuclear fusion Vol.47 No.5

<P>Construction of the Korea superconducting tokamak advanced research (KSTAR) tokamak is in its final phase. For the long-pulse KSTAR discharges, the ion cyclotron range of frequencies (ICRF) and neutral beam injection (NBI) heating systems are expected to play important roles through a selective heating of ions and electrons, control of the plasma pressure and current profiles, a core fuelling and beam diagnostics for the KSTAR. In addition, the ICRF system is expected to be used for possible discharge cleaning and assisting in the tokamak startup. In this paper, the recent progress in the development of the ICRF and the NBI heating systems is described. The four-strap ICRF antenna has been successfully tested for a voltage up to 41 kV for a pulse length of 300 s (to 46 kV for 20 s) in a test chamber. A prototype KSTAR NBI system has been developed. At present, the system has successfully produced a 1 MW beam power for 200 s and a 3.5 MW output beam power for 4 s.</P>